What Crinetics Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 16 |
| Total trades | 33 | 87 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 471 | 1,371,350 |
| Disposed | 1,905,000 | 3,033,580 |
| Net activity | −1,904,529 | −1,662,230 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −176,663 | $85.00 | −$15M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −80,000 | $85.00 | −$6.8M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −111,100 | $85.00 | −$9.44M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −111,100 | $85.00 | −$9.44M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −111,100 | $85.00 | −$9.44M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −111,100 | $85.00 | −$9.44M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −100,000 | $85.00 | −$8.5M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −110,000 | $85.00 | −$9.35M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −106,000 | $85.00 | −$9.01M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −136,805 | $85.00 | −$11.6M | 0 |
| Wierenga Wendell | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Kalofonos Isabel | Chief Commercial Officer | Sep 01 | Disposition to Issuer · D | −34,000 | $85.00 | −$2.89M | 0 |
| Struthers Richard Scott | President & CEO | Sep 01 | Disposition to Issuer · D | −1,000 | $85.00 | −$85K | 0 |
| Deardorf Caren | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Fust Matthew K | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Bedrosian Camille L | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Okey Stephanie | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Schilke Tobin | Chief Financial & Infra. Ofcr. | Sep 01 | Disposition to Issuer · D | −71,471 | $85.00 | −$6.08M | 0 |
| Vivaldi Coelho Rogerio | Director | Sep 01 | Disposition to Issuer · D | −5,925 | $85.00 | −$504K | 0 |
| Wierenga Wendell | Director | Sep 01 | Disposition to Issuer · D | −116,146 | $85.00 | −$9.87M | 5,925 |
Loading...